Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Chronic Spontaneous Urticaria Market In 2029?

The market size for chronic spontaneous urticaria has exhibited robust growth in the past few years. It is projected to expand from a worth of $2.06 billion in 2024 to $2.23 billion in 2025, showing a compound annual growth rate (CAGR) of 8.6%. The past growth can be ascribed to the advancement in diagnostic tools, increasing consciousness among healthcare providers, patient support and advocacy groups, continuous investigative studies and clinical trials for new treatment options, and rising health care spending.

What Growth Rate Is Forecasted for the Chronic Spontaneous Urticaria Market by 2029?

Over the coming years, the market size of chronic spontaneous urticaria is projected to experience significant expansion. By 2029, it is expected to reach $3.08 billion, with a compound annual growth rate (CAGR) of 8.4%. The sharp rise in the forecast period can be credited to a rise in diagnosed cases of CSU, an expanding patient demographic, advancements in healthcare infrastructure, a supportive regulatory environment, patient-focused care models, and economic progression in emerging markets. Noteworthy trends for the forecast stretch include breakthroughs in technology, progress in biological therapy, personalized healthcare, telemedicine and digital health, high-end diagnostic tools, AI, machine learning, and a surge in drug approvals and introductions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which Key Companies Are Shaping the Future of the Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Which Factors Are Driving Demand in the Chronic Spontaneous Urticaria Industry?

The upward trend of alcohol intake is projected to boost the chronic spontaneous urticaria market’s progress. The growth in alcohol use can be attributed to various factors such as societal standards, stress, advertising, affordability, and accessibility. Drinking alcohol could potentially worsen the symptoms of chronic spontaneous urticaria in certain individuals, leading to an increase in hives and swelling. For example, according to rehabs.UK, a supplier of addiction recovery support and counselling services in the UK, in February 2024, 55% of men were regularly consuming alcohol each week, while the percentage was 41% for women. Also, 8% of male subjects divulged almost daily alcohol consumption, in contrast to 5% of their female counterparts. From 2021 to 2022, related hospital admissions exclusively due to alcohol were 342,795, equating to a rate of 626 admissions per 100,000 individuals. Consequently, the rise in alcohol ingestion is propelling the advancement of the chronic spontaneous urticaria market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

How Is the Chronic Spontaneous Urticaria Market Segmented by Several Divisions?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

What are the Emerging Market Trends Driving the Growth of the Chronic Spontaneous Urticaria Industry?

Leading companies in the chronic spontaneous urticaria market are focusing on the creation of next-generation Briquilimab (JSP191) to improve treatment outcomes and minimize dosing intervals. This new generation Briquilimab (JSP191) is a monoclonal antibody created to target and eliminate specific immune cells, mainly those targeting CD47, like in chronic spontaneous urticaria. For illustration, in November 2023, Jasper Therapeutics Inc., a clinical-stage biotech company based in the US, reported that it has administered the first dose to a patient in a phase 1b/2a clinical study of Briquilimab for CSU. This milestone is fundamental in evaluating the safety and effectiveness of Briquilimab, a new-generation monoclonal antibody aimed at CD47, in managing this recurring hive and itch condition. The objective of the study is to determine how well Briquilimab can mitigate symptoms and enhance the life quality of patients affected by CSU.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Regions Are Driving Growth in the Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

This Report Delivers Insight On:

1. How big is the chronic spontaneous urticaria market, and how is it changing globally?

2. Who are the major companies in the chronic spontaneous urticaria market, and how are they performing?

3. What are the key opportunities and risks in the chronic spontaneous urticaria market right now?

4. Which products or customer segments are growing the most in the chronic spontaneous urticaria market?

5. What factors are helping or slowing down the growth of the chronic spontaneous urticaria market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model